Abstract:Objective: To explore the feasibility and accuracy of 0-1 h high sensitivity cardiac troponin I (hs-cTnI) concentration and its changes in judging non-ST segment elevation myocardial infarction (NSTEMI), and to investigate the feasibility of a simplified process. Methods: Patients with acute chest pain and suspected NSTEMI who were admitted to the emergency department of Fuwai Hospital, the First Affiliated Hospital of Sun Yat-sen University and Nanjing First Hospital from January 2017 to September 2020 were selected. Hs-cTnI test was carried out for the selected patients at the time of visit (0 h) and 1 h after visit. According to the 0-1 h hs-cTnI diagnostic process and threshold standard recommended by European Society of Cardiology (ESC) guidelines in 2015, the laboratory adjudication was determined. Cardiologists who did not participate in the project design and did not know the results of hs-cTnI test performed the clinical judgment according to the routine diagnosis and treatment process of emergency department. Taking clinical judgment as the gold standard, the diagnostic efficacy of 0-1 h hs-cTnI concentration and its change recommended by the guidelines for judging NSTEMI in Chinese population was analyzed. The guide process was simplified. Under the condition of not considering the time of chest pain, the guideline threshold was used for test and judgement, and the diagnostic efficacy of the simplified process was evaluated. Results: A total of 1 534 patients were enrolled in the study, aged (62±12) years and 952 (62.1%) patients were male. Among them, 402 patients (26.2%) were clinically diagnosed as NSTEMI and 1 132 patients (73.8%) were diagnosed as non-NSTEMI. According to the diagnosis and determination process recommended by the guidelines, NSTEMI was excluded in 672 patients (42.8%), and 464 patients (30.2%) were diagnosed as NSTEMI. The consistency rate with clinical determination reached 92.4% (1 050/1 136), the sensitivity of excluding diagnosis was 99.5% (95%CI: 98.0%-99.9%), the negative predictive value was 99.7% (95%CI: 98.8%-99.9%), and the negative likelihood ratio was 0.008 (95%CI: 0.002-0.335). The diagnostic specificity was 92.6% (95%CI: 90.9%-94.0%), the positive predictive value was 81.9% (95%CI: 78.0%-85.2%), and the positive likelihood ratio was 12.739 (95%CI: 10.356-15.670). According to the simplified process, NSTEMI was excluded in 675 patients (44.0%), and 463 patients (30.2%) were diagnosed as NSTEMI. The consistency rate with clinical judgment was 92.4% (1 051/1 138), the sensitivity of exclusion diagnosis was 99.3% (95%CI: 97.6%-99.8%), the negative predictive value was 99.6% (95%CI: 98.6%-99.9%), and the negative likelihood ratio was 0.012 (95%CI: 0.004-0.389). The diagnostic specificity was 92.6% (95%CI: 90.9%-94.0%), the positive predictive value was 81.9% (95%CI: 78.0%-85.2%), and the positive likelihood ratio was 12.705 (95%CI: 10.328-15.630). There was no significant difference in diagnostic efficacy between the simplified process and the recommended process (all P>0.05). Conclusion: The diagnostic process for judging NSTEMI according to the 0-1 h hs-cTnI concentration and its change criteria recommended by the 2015 ESC guidelines is applicable in the Chinese population and remains highly accurate in judging NSTEMI without considering the duration of chest pain at the time of presentation.

High-sensitivity cardiac troponin T for early prediction of non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome

Clinical application of high-sensitivity cardiac troponin T assay in the diagnosis of acute myocardial infarction

Evaluation of clinical performance of cardiac troponin Ⅰ in diagnosis and prognosis of non-ST elevation acute coronary syndromes

[Efficacy Analysis of High-Sensitivity Troponin I Concentration and Its Changes in the Diagnosis of Acute Myocardial Infarction].

Clinical Value of High Sensitivity Cardiac Troponin T in the Diagnosis of Acute Myocardial Infarction

Application of Enhanced Cardiac Troponin Ⅰ Determination in Clinical Diagnosis of Acute Coronary Syndrome

Age‐Specific 99th Percentile Cutoff of High‐Sensitivity Cardiac Troponin T for Early Prediction of Non‐ST‐Segment Elevation Myocardial Infarction (NSTEMI) in Middle‐Aged Patients

Performance of high-sensitivity cardiac troponin T versus I for the early diagnosis of myocardial infarction

Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome

Machine Learning Diagnostic Model for Early Stage NSTEMI: Using hs-cTnI 1/2h Changes and Multiple Cardiovascular Biomarkers

The Combination of Creatine Kinase-Myocardial Band Isoenzyme and Point-of-care Cardiac Troponin/contemporary Cardiac Troponin for the Early Diagnosis of Acute Myocardial Infarction

Performance evaluation of a novel high-sensitivity cardiac troponin T assay: analytical and clinical perspectives

Study on application of cTnT for earlier diagnosis of acute myocardial infarction

Clinical Implication of Mildly Elevated Serum Hs-Tnt in Elderly Patients with Acute Coronary Syndrome

Evaluation Of The 0 H/1 H High-Sensitivity Cardiac Troponin T Algorithm In Diagnosis Of Non-St-Segment Elevation Myocardial Infarction (Nstemi) In Han Population

Diagnosis of acute myocardial infarction by cardiac markers assay

Time from symptom onset influences high-sensitivity troponin T diagnostic accuracy for the diagnosis of acute myocardial infarction

Diagnosis of Acute Myocardial Infarction in Patients with Renal Insufficiency Using High-Sensitivity Troponin T

Saturday, 31 August 2013

The Analytical Performance Assessment of High-Sensitivity Cardiac Troponin T Reference Intervals Investigation

The Diagnosis and Prognostic Value of Admission Cardiac Troponin I on Acute Myocardial Infarction